All deliverables
Digital · HCPs or patients

HTML Email.
Mobile-responsive. Cross-client tested. Never broken in Outlook.

Audience
HCPs or patients
Format
Single-file HTML
Testing
Outlook, Gmail, Apple Mail
Price from
£260

A production-ready HTML email built for real-world inboxes.

Pixel builds every email in MJML — a purpose-built email markup language that compiles to cross-client-safe HTML. This isn't a drag-and-drop builder output; it's hand-crafted email code that handles the inconsistencies of Outlook's Word rendering engine, Gmail's CSS stripping, and Apple Mail's dark mode inversion.

All CSS is inlined at build time. Images are specified at the correct retina resolution. Unsubscribe links, plain-text alternatives, and preheader text are all included as standard. The final output is a single HTML file that is ready to upload directly to your ESP.

For HCP-targeted emails, Reg reviews against ABPI 2024 digital communications guidance, including required statements, subject line compliance, and audience targeting standards. Series emails are built to a consistent template spec so each email in the sequence looks coherent with the last.

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope Single email · 1 message 3-email series 5-email nurture series + A/B variants
Team Sys, Medi/Ink, Pixel, Pace + Aria + Reg (HCP) + Signal
Price range ~£260 ~£490 ~£980
Best for Announcement, data alert, single CTA Multi-step evidence journey, product launch sequence Full HCP nurture programme, patient activation campaign

What it looks like.

HTML Email — Outlook/Gmail render preview
Hartwell Pharmaceuticals · Medical Affairs
New data in plaque psoriasis.
72% PASI 90 at week 16.
Dear Dr. [Surname],

The VERIFY-1 trial results for Verixtol® (verixtumab 150mg) are now published in the New England Journal of Medicine. The 52-week data confirm durable response with a well-characterised safety profile.
72%
PASI 90 at week 16 vs 4% placebo (p<0.0001, n=312)1
1. VERIFY-1. NEJM. 2024;391:2341–2354. This email is intended for UK healthcare professionals only. To unsubscribe, click here.
Email 2 of 3 — Verixtol Evidence Series
Series 2 of 3 · Verixtol® Evidence Series
The safety profile.
52 weeks of data.
In the first email in this series, we looked at the efficacy data from VERIFY-1. In this email, we focus on what 52 weeks of follow-up revealed about Verixtol's safety and tolerability in a real-world-like population.
3%
Serious AEs
2.1%
Discontinuation
0%
IBD events
Email 1/5 — Nurture series (A/B Variant A)
Variant A — Subject: "The dermatology data your patients are asking about"
Your patients are searching for answers about plaque psoriasis.
Here's the data that answers their questions — and informs your conversations.
Over the next five emails, we'll take you through the complete VERIFY programme: what the data shows, what it means for your practice, and what patients are asking about Verixtol — including the questions they're finding online.
In this series:
Email 1: The efficacy story → You are here
Email 2: 52-week safety data
Email 3: The patient experience
Email 4: Dosing & administration
Email 5: How to access Verixtol for your patients

Full rendered examples will be available at launch.

ABPI 2024 Compliance

HCP-targeted HTML emails are subject to ABPI 2024 digital communications guidance. Subject lines, sender identity, and unsubscribe mechanisms are all reviewed. Patient emails follow UK GDPR and direct marketing regulations.

Start your HTML Email.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →